Skip to main content
Nitya Nathwani, MD, Oncology, Duarte, CA, City of Hope Comprehensive Cancer Center

NityaAtulNathwaniMD

Oncology Duarte, CA

Assistant Professor

Dr. Nathwani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Nathwani's full profile

Already have an account?

Education & Training

  • University of Southern California/LAC+USC Medical Center
    University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2009 - 2010
  • University of Southern California/LAC+USC Medical Center
    University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2008 - 2009
  • University of Southern California/LAC+USC Medical Center
    University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2007 - 2008
  • University of Southern California/LAC+USC Medical Center
    University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 2004 - 2007
  • Topiwala National Medical College
    Topiwala National Medical CollegeClass of 2002

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2006 - 2026
  • AK State Medical License
    AK State Medical License 2023 - 2024
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
    Nitya Nathwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...
    Nitya Nathwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results
    Nitya Nathwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults with Multiple Myeloma to Drive Personalized Treatment Decisions 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab ﴾Dara﴿, Bortezomib ﴾V﴿, Lenalidomide ﴾R﴿, and De... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative Neoplasm
    OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative NeoplasmApril 11th, 2018

Other Languages

  • Hindi

Hospital Affiliations